Fungal infections should be part of the core outcome set for COVID-19.

Verweij, Paul E; Alanio, Alexandre

Verweij, Paul E; Alanio, Alexandre.

Verweij PE; Department of Medical Microbiology and Center of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Centre, Nijmegen, Netherlands. Electronic address: paul.verweij@radboudumc.nl.
Alanio A; Mycology-Parasitology Department, Hôpital Saint-Louis, Molecular Mycology Unit, CNRS UMR2000, National Reference Centre for Invasive Mycoses and Antifungals, Institut Pasteur, Université de Paris, Paris, France.

Lancet Infect Dis ; 21(6): e145, 2021 06.

Article in English | MEDLINE | ID: covidwho-960190

Subject(s)

COVID-19/complications; Mycoses/complications; COVID-19/diagnosis; Humans; Influenza, Human; Intensive Care Units; Mycoses/diagnosis; Mycoses/drug therapy; Mycoses/microbiology; Outcome Assessment, Health Care; Pulmonary Aspergillosis; Risk Factors; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Mycoses Type of study: Diagnostic study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Lancet Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google